nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2011 | Short Communication

Androgen deprivation therapy influences the uptake of ¹¹C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study

verfasst von: Chiara Fuccio, Riccardo Schiavina, Paolo Castellucci, Domenico Rubello, Giuseppe Martorana, Monica Celli, Claudio Malizia, Marta Barios Profitos, Maria Cristina Marzola, Vincenzina Pettinato, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The influence of androgen deprivation therapy (ADT) on ¹¹C-choline uptake in patients with prostate cancer (PC) has not yet been clarified. The aim of our study was to investigate this issue by means of sequential ¹¹C-choline positron emission tomography (PET)/CT in patients with recurrent PC.

Methods

We retrospectively studied 14 recurrent PC patients (mean age 67 years, range 55–82) during follow-up after radical prostatectomy (RP) with rising serum prostate-specific antigen (PSA) levels. All patients had undergone at least two consecutive ¹¹C-choline PET/CT scans: the first ¹¹C-choline PET/CT before commencing ADT and the second ¹¹C-choline PET/CT after 6 months of ADT administration.

Results

The mean serum PSA level before ADT was 17.0 ± 44.1 ng/ml. After 6 months of ADT administration the PSA value significantly decreased in comparison to baseline (PSA = 2.4 ± 3.1 ng/ml, p < .025). Moreover, before starting ADT, 13 of 14 patients had positive ¹¹C-choline PET/CT for metastatic spread, while after 6 months of ADT administration in 9 of 14 patients ¹¹C-choline PET/CT became negative.

Conclusion

These preliminary results suggest that ADT significantly reduces ¹¹C-choline uptake in androgen-sensitive PC patients.

Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59:893–9.PubMedCrossRef

Kataja VV, Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 2005;16 Suppl 1:i34–6.PubMedCrossRef

Flüchter SH, Weiser R, Gamper C. The role of hormonal treatment in prostate cancer. Recent Results Cancer Res 2007;175:211–37.PubMedCrossRef

Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005;66:350–5.PubMedCrossRef

De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 2010;194:1427–33.PubMedCrossRef

Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008;179:906–10.PubMedCrossRef

Cher ML, Bianco Jr FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387–91.PubMedCrossRef

Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 2004;94:299–302.PubMedCrossRef

Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171:2260–4.PubMedCrossRef

10.

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337–40.PubMedCrossRef

11.

Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2010. [Epub ahead of print].

12.

Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005;76:4–10.PubMedCrossRef

13.

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572–83.PubMedCrossRef

14.

Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065–73.PubMedCrossRef

15.

Pascali C, Bogni A, Iwata R, Cambiè M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Comp Radiopharm 2000;43:195–203.CrossRef

16.

Fanti S, Nanni C, Ambrosini V, Gross MD, Rubello D, Farsad M. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging 2007;51:260–71.PubMed

17.

Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008;49:2031–41.PubMedCrossRef

18.

Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18–23.PubMedCrossRef

19.

Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394–400.PubMedCrossRef

20.

Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:301–9.PubMedCrossRef

21.

Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:1106–16.PubMedCrossRef

22.

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011;38:55–63.PubMedCrossRef

23.

Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413–39.PubMedCrossRef

24.

Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668–73.PubMedCrossRef

25.

Al-Saeedi F, Welch AE, Smith TA. [methyl-3H]Choline incorporation into MCF7 tumour cells: correlation with proliferation. Eur J Nucl Med Mol Imaging 2005;32:660–7.PubMedCrossRef

26.

Al-Saeedi F, Smith T, Welch A. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay. Anticancer Res 2007;27:901–6.PubMed

Titel: Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study
verfasst von: Chiara Fuccio
Riccardo Schiavina
Paolo Castellucci
Domenico Rubello
Giuseppe Martorana
Monica Celli
Claudio Malizia
Marta Barios Profitos
Maria Cristina Marzola
Vincenzina Pettinato
Stefano Fanti
Publikationsdatum: 01.11.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1867-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Androgen deprivation therapy influences the uptake of ¹¹C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study

Abstract

Purpose

Methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2011

Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection

Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?

Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis

Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study

First ex vivo study demonstrating that 99mTc-NTP 15-5 radiotracer binds to human articular cartilage